Commonwealth Medicine, Clinical Pharmacy Services
Health Economics | Health Law and Policy | Health Policy | Health Services Administration | Health Services Research | Pharmacoeconomics and Pharmaceutical Economics | Pharmacy Administration, Policy and Regulation
Specialty drug spend increased by 15 percent to $121 billion in 2015 and is projected to rise even more. Budget-conscious payers need to implement novel management strategies that anticipate the cost of specialty medications before they’re available. A summary of efficacy data for high-impact specialty pipeline drugs expected to reach the market, including their place in therapy and budgetary impact. Also featured are strategies to mitigate costs of these cutting-edge medications and compare them to current therapy options.
specialty medications, specialty drugs, drug spend, pharmacy, drug utilization review
DOI of Published Version
Eastern Medicaid Pharmacy Administrators Association 40th Annual Meeting
Trask NM. (2016). Planning for the 2017 Specialty Drug Spend: When Costs are Steep but Pockets are Not Deep. Commonwealth Medicine Publications. https://doi.org/10.13028/bvn5-f308. Retrieved from https://escholarship.umassmed.edu/commed_pubs/160
Health Economics Commons, Health Law and Policy Commons, Health Policy Commons, Health Services Administration Commons, Health Services Research Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons